

IN THE CLAIMS

Please cancel claims 18-20, 22-24, 27, 29 and 30-31

REMARKS

Reconsideration of this application and entry of the amendments is respectfully requested. Claims 18-20, 22-24, 27, 29 and 30-31 have been canceled. Therefore, claims 1-17, 21, 25-26, 28, and 32 are pending.

Applicants have cancelled claims without prejudice, and reserve the right to pursue the cancelled claims in a later continuation application.

I. Restriction Requirement

Applicant acknowledges the restriction requirement, and hereby affirms the election to prosecute the invention of Group I, namely claims 1-17, 21, 25, 26, 28 and 30-32, without traverse. Claims 18-20, 22-24, 27 and 29 have been cancelled without prejudice. Applicant retains the right to pursue the subject matter of the cancelled claims in a later-filed application.

II. Claim Objections - Sequence Listing Requirement

The Action alleges that claim 1 is objected to for failing to comply with sequence rule requirements. This objection is respectfully traversed.

The sequence rule requirements only apply for recitations of an amino acid sequence which exceed three amino acid residues in length. Claim 1 does not contain a sequence of